Recall Action Notification
Edwards Lifesciences IntraClude Intra-aortic Occlusion Device
Important information on the System for Australian Recall Actions

The TGA publishes information about therapeutic goods supplied in the Australian market that have been subject to a recall action in a publicly searchable database.

Recall action means action taken by the responsible entity (being the person who is responsible for taking the recall action) to resolve a problem with therapeutic goods supplied in the Australian market that have, or may potentially have, deficiencies relating to safety, quality, efficacy (performance) or presentation.

- Recall actions include: the permanent removal of therapeutic goods from supply in the market, the taking of corrective action in relation to therapeutic goods (such as repair, modification, adjustment or relabelling) and, in the case of medical devices that have been implanted into patients, the issuing of a hazard alert containing information for health practitioners on how to manage patients.


- If you are taking a medicine, using a medical device or have had a medical device implanted into you, that is the subject to a recall action, and you have any concerns you should seek advice from a health professional. [http://www.healthdirect.org.au/](http://www.healthdirect.org.au/)

About the release of this information

While reasonable care is taken to ensure that the information is an accurate record of recall actions that responsible entities have reported to the TGA or of which the TGA has become aware, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose.

To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

The information contained in the SARA database is released under s 61(5C) of the Therapeutic Goods Act 1989. Copyright restrictions apply to the System of Australian Recall actions (SARA) [http://tga.gov.au/about/website-copyright.htm](http://tga.gov.au/about/website-copyright.htm).
# Recall detail

<table>
<thead>
<tr>
<th>Type of Product</th>
<th>Medical Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGA Recall Reference</td>
<td>RC-2019-RN-00086-1</td>
</tr>
<tr>
<td>Product Name/Description</td>
<td>Edwards Lifesciences IntraClude Intra-aortic Occlusion Device</td>
</tr>
<tr>
<td>Model</td>
<td>ICF100</td>
</tr>
<tr>
<td>Supplied under SAS</td>
<td></td>
</tr>
<tr>
<td>Recall Action Level</td>
<td>Hospital</td>
</tr>
<tr>
<td>Recall Action Classification</td>
<td>Class II</td>
</tr>
<tr>
<td>Recall Action Commencement Date</td>
<td>18/01/2019</td>
</tr>
<tr>
<td>Responsible Entity</td>
<td>Edwards Lifesciences Pty Ltd</td>
</tr>
<tr>
<td>Reason / Issue</td>
<td>Edwards Lifesciences has identified a potential safety risk which may occur during the use of the IntraClude intra-aortic occlusion device (ICF100). Edwards Lifesciences has received customer reports regarding an inter-lumen leak between the cardioplegia lumen and pressure lumen in the device. If present, the leak will be detected after the device is advanced into the ascending aorta, but before the balloon is inflated. The detection will occur when, as stated in the Instructions for Use, the aortic root vent is turned on, which is the last step prior to inflating the balloon. When present, the leak will result in aortic root pressure dropping to 0 mmHg or less due to the vacuum being pulled on the aortic root vent line. No reports of illness or injury have been reported in any of the complaints relating to this issue.</td>
</tr>
<tr>
<td>Recall Action</td>
<td>Product Defect Alert</td>
</tr>
<tr>
<td>Recall Action Instructions</td>
<td>Customers are advised to review the contents of the customer letter and understand the potential hazards associated with Inter-Lumen Leaks. The affected product may continue to be used. Customers are asked to complete and return the acknowledgement form attached to the customer letter.</td>
</tr>
<tr>
<td>Contact Information</td>
<td>02 8899 6304 - Meryl Musson</td>
</tr>
</tbody>
</table>

## Footnotes

1. Type of Product: Medicine, Medical Device, or Biological
2. TGA Recall Reference: Unique number given by the TGA
3. Product Name/Description: Brand name (including active ingredient for medicines) and may include generic reference
for the kind of medical devices. Includes all necessary information such as affected: catalogue / model and / or batch / serial numbers.

iv Recall Action Level: The level to which the recall action is to be undertaken. This is based on the significance of the risk and the channels through which the goods have been distributed. The recall action levels are / Wholesale / Hospital / Retail / Consumer.

  • Wholesale - includes wholesalers and state purchasing authorities.
  • Hospital - includes nursing homes and institutions, hospital pharmacists, ambulance services, blood and tissue banks and laboratories as well as wholesale as appropriate.
  • Retail - includes retail pharmacists, medical, dental and other health care professionals as well as wholesale and hospital as appropriate.
  • Consumer - includes patients and consumers, as well as wholesale, hospital and retail levels as appropriate.

v Recall Action Classification: Recall actions of therapeutic goods are classified based on the potential risk the deficiency poses to patients / consumers. They are classified as Class I, Class II or Class III.

  • Class I recall action occurs when the product deficiency is potentially life-threatening or could cause a serious risk to health.
  • Class II recall action occurs when the product deficiency could cause illness, injury or result in mistreatment, but are not Class I.
  • Class III recall action occurs when the product deficiency may not pose a significant hazard to health, but action may be initiated for other reasons eg. quality related issues.

vi Recall Action Commencement Date: The date the recall strategy and communication was agreed by the TGA.

vii Responsible Entity: Sponsor / Supplier / Importer responsible for the recall actions.

viii Reason / Issue: Reason for the recall action.

ix Recall Action: Recall action is an action taken to resolve a problem with a therapeutic good already supplied in the market for which there are issues or deficiencies in relation to safety, quality, efficacy (performance) or presentation.

There are three distinct recall actions - recall, recall for product correction and hazard alert.

  • Recall - The permanent removal of an affected therapeutic good from supply or use in the market.
  • Recall for product correction - Repair, modification, adjustment or re-labelling of a therapeutic good. The corrective action may take place at the user's premises or any other agreed location.
  • Hazard alert - Information issued to healthcare professionals about issues or deficiencies relating to an implanted medical device or biological product and advice about the ongoing management of patients.

x Recall Action Instructions: What the customer should do.

xi Contact Information: Who the customer should contact for additional information and clarification regarding the recall action.